Peer-Reviewed Publication
J Neurooncol2022;160(1):233-240.October 1, 2022Journal Article
Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.
Caressa Hui1, Vera Qu1, Jen-Yeu Wang1, Rie von Eyben1, Yu-Cheng Chang2, Po-Lin Chiang2, Chih-Hung Liang2, Jen-Tang Lu2, Gordon Li3, Melanie Hayden-Gephart3, Heather Wakelee4, Joel Neal4, Kavitha Ramchandran4, Millie Das4, Seema Nagpal5, Scott Soltys1, Nathaniel Myall6,7, Erqi Pollom8,9
1Department of Radiation Oncology, Stanford University, Palo Alto, CA, USA.
2Vysioneer Inc, Cambridge, MA, USA.
3Department of Neurosurgery, Stanford University, Palo Alto, CA, USA.
4Department of Medical Oncology, Stanford University, Palo Alto, CA, USA.
5Department of Neurology, Stanford University, Palo Alto, CA, USA.
6Department of Medical Oncology, Stanford University, Palo Alto, CA, USA. nmyall@stanford.edu.
7Department of Medical Oncology, Stanford University, 300 Pasteur Dr Rm JC007, Stanford, CA, 94305, USA. nmyall@stanford.edu.
8Department of Radiation Oncology, Stanford University, Palo Alto, CA, USA. erqiliu@stanford.edu.
9Department of Radiation Oncology, Stanford University, 875 Blake Wilbur Drive, Stanford, CA, 94305, USA. erqiliu@stanford.edu.
Abstract
PURPOSE: Although osimertinib has excellent intracranial activity in metastatic non-small cell lung cancer (NSCLC) with exon 19 deletion or L858R EGFR alterations, measures of local control of brain metastases are less well-reported. We describe lesion-level outcomes of brain metastases treated with osimertinib alone.
METHODS: We retrospectively reviewed patients with EGFR-mutant NSCLC with untre…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans